Market Closed -
Nasdaq
04:00:03 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
11.87
USD
|
-0.84%
|
|
+5.32%
|
-21.65%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,109
|
3,808
|
1,149
|
1,072
|
843.6
|
-
|
-
|
Enterprise Value (EV)
1 |
1,771
|
3,468
|
712
|
589.2
|
315.2
|
487.8
|
488.4
|
P/E ratio
|
-12.4
x
|
-22.6
x
|
-4.5
x
|
-3.39
x
|
-4.39
x
|
-3.21
x
|
-4.11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
25.7
x
|
315
x
|
31.6
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
9.61
x
|
182
x
|
18.3
x
|
EV / EBITDA
|
-14.9
x
|
-16.1
x
|
-3.15
x
|
-1.98
x
|
-1.35
x
|
-1.67
x
|
-1.63
x
|
EV / FCF
|
-13.9
x
|
-16.9
x
|
-3.3
x
|
-2.83
x
|
-1.36
x
|
-1.7
x
|
-1.8
x
|
FCF Yield
|
-7.21%
|
-5.92%
|
-30.3%
|
-35.4%
|
-73.8%
|
-58.7%
|
-55.4%
|
Price to Book
|
6.91
x
|
10.5
x
|
2.75
x
|
2.45
x
|
1.87
x
|
3.07
x
|
3.39
x
|
Nbr of stocks (in thousands)
|
40,614
|
45,306
|
57,069
|
70,766
|
71,013
|
-
|
-
|
Reference price
2 |
51.94
|
84.06
|
20.14
|
15.15
|
11.88
|
11.88
|
11.88
|
Announcement Date
|
3/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
32.81
|
2.678
|
26.73
|
EBITDA
1 |
-
|
-118.6
|
-216
|
-225.9
|
-298.1
|
-232.7
|
-292.1
|
-298.7
|
EBIT
1 |
-
|
-118.8
|
-216.5
|
-227.3
|
-299.5
|
-238.1
|
-299.6
|
-317.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-725.7%
|
-11,189.45%
|
-1,186.17%
|
Earnings before Tax (EBT)
1 |
-
|
-118.1
|
-164.6
|
-221.3
|
-276.9
|
-183.7
|
-290.1
|
-306.2
|
Net income
1 |
-46.38
|
-118.5
|
-158.7
|
-236.8
|
-292.2
|
-192.8
|
-299.3
|
-325.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-587.63%
|
-11,176.77%
|
-1,217.34%
|
EPS
2 |
-8.160
|
-4.190
|
-3.720
|
-4.480
|
-4.470
|
-2.704
|
-3.702
|
-2.894
|
Free Cash Flow
1 |
-
|
-127.7
|
-205.3
|
-215.5
|
-208.4
|
-232.5
|
-286.6
|
-270.8
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-708.66%
|
-10,702.45%
|
-1,012.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/6/20
|
3/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
40.56
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-47.98
|
-
|
-
|
-
|
-51.4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-48.19
|
-57.88
|
-63.46
|
-54.19
|
-51.75
|
-64.95
|
-103.9
|
-62.72
|
-67.92
|
-24.76
|
-66.78
|
-68.96
|
-77.18
|
-71.61
|
-73.55
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-61.06%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-48.1
|
-57.45
|
-63.04
|
-52.29
|
-48.52
|
-60.84
|
-99.46
|
-55.51
|
-61.07
|
10.18
|
-57.05
|
-59.96
|
-76.57
|
-69.75
|
-71.5
|
Net income
1 |
-50.06
|
-59.08
|
-68.36
|
-54.4
|
-54.97
|
-63.22
|
-112.5
|
-55.53
|
-60.92
|
10.07
|
-59.63
|
-62.82
|
-80.14
|
-71.17
|
-73.67
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
24.82%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.110
|
-1.310
|
-1.340
|
-0.9600
|
-0.9200
|
-1.070
|
-1.850
|
-0.7900
|
-0.8300
|
0.1400
|
-0.8363
|
-0.8732
|
-1.043
|
-0.9175
|
-0.9475
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/9/22
|
11/9/22
|
3/1/23
|
5/10/23
|
8/9/23
|
11/6/23
|
2/27/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
339
|
340
|
437
|
483
|
528
|
356
|
355
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-128
|
-205
|
-215
|
-208
|
-232
|
-287
|
-271
|
ROE (net income / shareholders' equity)
|
-
|
-104%
|
-47.2%
|
-59.4%
|
-67.1%
|
-49.4%
|
-102%
|
-123%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
7.520
|
8.000
|
7.320
|
6.180
|
6.340
|
3.870
|
3.500
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.76
|
6.11
|
2.55
|
0.58
|
6.44
|
2.8
|
3.95
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
19.63%
|
104.64%
|
14.79%
|
Announcement Date
|
3/6/20
|
3/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
11.88
USD Average target price
33.4
USD Spread / Average Target +181.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.65% | 843M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|